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Approximately 35% of patients referred for the performance 
of diagnostic stress testing are either unable to exercise or 
cannot exercise maximally (1). The current alternatives for 
stress testing in these patients include the vasodilators dipyr- 
idamole and adenosine, dobutamine and other less widely 
accepted techniques, including transesophageal p cing (2). 
The vasodilator stressors are very effective alternatives to 
exercise in combination with myocardial perfusion imaging but 
appear to be less effective in combination with echocardiogra- 
phy and electrocardiography (3). Dobutamine induces isch- 
emia by increasing myocardial oxygen consumption and may 
be effectively combined with either echocardiography or per- 
fusion scintigraphy, but in combination with electrocardiog- 
raphy alone it is insensitive for the diagnosis of coronary 
disease in unselected patients (4). 
However, the current pharmacologic stress techniques have 
significant limitations. Dipyridamole is contraindicated in pa- 
tients with asthma or severe conduction disturbances. The test 
may be unreliable if the patient ingests caffeine on the day of 
the test, and some patients appear to be unresponsive to 
conventional doses of dipyridamole. Serious side effects occur 
in 1.2% of patients using a high dose dipyridamole protocol 
(5), but minor side effects are frequent even at a low dose (6). 
Dobutamine is contraindicated in patients with severe hyper- 
tension and rhythm disturbances; erious complications occur 
in 0.5%, and the performance of maximal stress may be limited 
by side effects in >10% of patients (7). Atropine administra- 
tion has been found to be a useful adjunct to both dobutamine 
and dipyridamole stress echocardiography but is contraindi- 
cated in patients with prostatic enlargement or glaucoma. A
new pharmacologic stressor that did not share these disadvan- 
tages would be a useful addition to the diagnostic armamen- 
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tarium. Such an agent should have a number of the following 
desirable qualities: 
1. Feasible (well tolerated, minimally invasive, protocol of 
reasonable duration) 
2. Inexpensive 
3. Low frequency of contraindications and side effects 
4. Development of cardiac work loads similar to those ob- 
tained with exercise 
5. Reproducible dose-response 
6. Offer useful stress electrocardiographic data in unselected 
populations 
7. Applicability with both perfusion scintigraphy and stress 
echocardiography 
8. Accuracy and prognostic value comparable or superior to 
currently available techniques 
Arbutamine. Arbutamine isa sympathomimetic compound 
that has potent and short-acting nonselective beta-agonist and 
some mild alpha-agonist activity (8). Although related to 
dobutamine, which was developed to have a predominantly 
inotropic effect, arbutamine was designed as a stress agent. 
Thus, the chronotropic and inotropic effects of arbutamine are 
more balanced than those of dobutamine, so that in animal 
models arbutamine has been shown to increase heart rate and 
dP/dt in a dose-dependent manner without producing hypo- 
tension. Whether these experimental findings pertain to clini- 
cal use remains undefined. 
Whatever the merits of arbutamine in relation to dobut- 
amine, a particularly interesting aspect of the arbutamine 
stress test is its automated delivery system. The software of this 
device incorporates a closed-loop algorithm that adjusts the 
infusion rate of arbutamine on the basis of feedback from the 
patient's hemodynamic response so as to attain a chosen heart 
rate increment up to a preselected heart rate target. In 
addition to monitoring the heart rate and blood pressure, a 
series of alerts and alarms notify the physician performing the 
test of untoward evelopments or inappropriate r sponses. 
Accuracy of arbutamine stress testing. The three multi- 
center studies (9-ll) of arbutamine stress published in this 
issue of the Journal document the feasibility and safety of the 
technique in large numbers of patients. The results of arbu- 
tamine imaging combinations are comparable tothose obtain- 
able with other pharmacologic stressors. Thus, arbutamine 
stress echocardiography (9) had a sensitivity of 84% for the 
identification of >50% stenoses at coronary angiography and a 
normalcy rate of 96%, and arbutamine thallium single-photon 
emission computed tomography (SPECT) had a sensitivity of 
87% and a normalcy rate of 90% (10). The use of chest pain 
evaluation and ST segment changes in the study of Dennis et 
al. (11) gave a sensitivity of 84% and a normalcy rate of 80%. 
The sensitivity of a test (its ability to correctly identify 
disease when disease ispresent), and its specificity (its ability to 
correctly exclude disease when it is absent) are variables that, 
unlike predictive values, are independent of disease preva- 
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lence. However, these variables are not independent of study 
design and population selection. Factors that may enhance the 
sensitivity of noninvasive tests for coronary artery disease 
include selection of patients with a high prevalence of myocar- 
dial infarction and extensive coronary disease. Each of these 
studies of arbutamine is characterized by the inclusion of 
patients with previous myocardial infarction, which accounted 
for nearly 50% of the patients in the scintigraphy group (10). 
As expected, the sensitivity of arbutamine thallium SPECT in 
a subgroup without myocardial infarction was lower than that 
for the overall group (79% vs 87%). Similarly, the sensitivity of 
arbutamine chocardiography for ischemia (stress-induced 
wall motion abnormality) was less than its sensitivity for 
detection of coronary disease (any wall motion abnormality). 
The ability to designate the presence or absence of disease 
is implicit in the analysis of sensitivity and specificity. The use 
of an angiographic definition, although conventional, is limited 
by the poor correlation between flow limitation and stenosis 
severity (12). The arbitrary cutoff level of "significant" disease 
influences test sensitivity and specificity. Increasing this cutoff 
from a percent diameter stenosis of 50% to 70% increases the 
sensitivity of noninvasive techniques at the cost of a lower 
specificity. Unfortunately, this balance is obscured by the 
absence of a specificity group in the design used for these 
studies of arbutamine stress (9-11), which instead involve a 
low probability ("normalcy") group. 
Specificity and normalcy are two expressions of the ability 
of a test to exclude disease when none is present. The use of 
specificity is attended by a number of disadvantages: 1) The 
size of this group is limited by the proportion of available 
patients who have truly negative findings on the coronary 
angiogram. 2) Use of a specific cutoff (e.g., <70% diameter 
stenoses) categorizes patients with lesser but possibly physio- 
logically significant stenoses as having "no disease," so that an 
ischemic response is mistakenly categorized as a false positive 
response. 3) Many patients undergo angiography for the 
evaluation of clinical symptoms. Even if there is no significant 
stenosis in an epicardial coronary vessel, an ischemic response 
(labeled as false positive) may arise because of abnormalities 
in the coronary circulation unrelated to epicardial coronary 
disease. 4) False positive responses will be disproportionately 
represented if the selection of patients for angiography is at all 
influenced by the result of the noninvasive test ("posttest 
referral bias"). 5) There is the practical issue of recruitment of 
patients into the study. Once patients have been shown to have 
totally normal coronary arteries, it is difficult to request hat 
these patients undergo another stress test. Conversely, it is 
neither ethical nor cost-effective to catheterize known normal 
subjects for the purpose of such a study. For all these reasons, 
normalcy data have been used previously in combination with 
both perfusion scintigraphy (13,14) and stress echocardiogra- 
play (15). Nevertheless, despite all these considerations, the 
acquisition of a true specificity group is not impossible, and this 
approach has been used in most previous studies of stress 
testing and stress imaging techniques. 
The major problem in studying a normalcy group is that this 
group may not conform to the usual population among whom 
the test is used. The present studies (9-11) of arbutamine 
stress have limited this problem by focusing on a group of older 
patients with cardiac risk factors. This focus has the unfortu- 
nate implication that a number of such patients will have 
coronary disease: Thus, the "normalcy" rate of 90% in the 
arbutamine thallium SPECT study (10) is lower than that 
usually reported for normal subjects. The use of a normalcy 
group does not preclude the performance of a specificity 
analysis, but in the present studies, the only patients with 
<50% stenoses had initially been recruited in the expectation 
of a positive test response and consequently represent a highly 
biased group. Of such a cohort in the arbutamine thallium 
SPECT study (10), only two patients had a negative response 
on the thallium scans (specificity 25%), and in the arbutamine 
stress echocardiography study (9), the specificity in this sub- 
group of only 16 patients was 36%. Clearly, these are unrep- 
resentative values in highly biased subgroups of patients. 
Arbutamine stress electrocardiography. In patients who 
are unable to exercise, the results of pharmacologic stress 
electrocardiography have been disappointing (4). The relative 
ability of arbutamine to engender ischemia on stress testing 
(defined as ST segment changes with or without chest pain) 
appears ambiguous. In each of the present studies, the sensi- 
tivity of ST segment changes alone for the development of 
ischemia during arbutamine stress was on the order of 50%. In 
the study by Dennis et al. (11), the sensitivity was enhanced by 
the use of angina (with or without ST segment changes) as a 
positive response. However, pain is a difficult end point to 
standardize, particularly in a multicenter study. Moreover, 
nonspecific hest discomfort is also commonly seen during 
dobutamine stress, where its inclusion as a criterion of test 
positivity has enhanced sensitivity while having an adverse 
impact on specificity. In the absence of a true specificity group, 
this effect of using angina as a criterion of positivity might not 
be appreciated, although the normalcy rate of 80% was the 
lowest of all three studies. Finally, although the sensitivity of 
ST segment changes in response to arbutamine was not 
significantly different from those induced by exercise, the 
performance of submaximal exercise in a proportion of pa- 
tients may have compromised the exercise electrocardio- 
graphic response. 
Use of arbutamine in patients able to exercise. The efficacy 
of the existing nonexercise stressors, the technical difficulties 
posed by imaging a hyperventilating, tachycardic patient after 
exercise (especially with echocardiography) and the possible 
benefits of being able to image the heart during stress have led 
to the suggestion that nonexercise stressors be used even in 
patients who are able to exercise maximally. Unfortunately, 
pharmacologic stress has a number of shortcomings for the 
evaluation of patients with suspected coronary disease: 
l) Pharmacologic stress lacks the functional implications of 
ischemia developing during exercise--for example, the devel- 
opment of ischemia during the second stage of a Bruce 
protocol is more easy to equate with functional performance 
than the development of ischemia at a similar heart rate in 
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response to 30 to 40 ~tg/kg body weight per min of dobutamine. 
Similarly, the reassurance that patients derive from exercising 
for a reasonable period during an exercise protocol is not easily 
replicated by a pharmacologic stress, albeit to a similar work 
load. 2) Aspects of the exercise test other than ST segment 
changes or stress imaging responses are important and include 
the presence or absence of symptoms, exercise-induced ar- 
rhythmias, exercise capacity and hemodynamic response. Anal- 
ogous data with nonexercise stress are either wanting or less 
meaningful. 3) The prognostic mplications of exercise testing 
have not yet been replicated with equivalent nonexercise data. 
4) Even when an imaging test is performed, additional ST 
segment changes may be reassuring in the context of nondiag- 
nostic or equivocal imaging results, but with conventional 
pharmacologic stressors, the ST segment response is of limited 
sensitivity. 
The studies of arbutamine in this issue of the Journal do not 
provide sufficient data to justify its recommendation n prefer- 
ence to exercise stress in those subjects who can exercise. 
Comparisons of the hemodynamic responses to stress have 
shown a lower peak heart rate, blood pressure and rate- 
pressure product with arbutamine than with exercise, afinding 
analogous to that obtained by comparison with dobutamine 
and exercise stress (16). The comparable overall heart rate and 
blood pressure response in one study (10) suggest that some of 
the patients may have exercised submaximally. Although the 
overall sensitivity of arbutamine and exercise stress were 
comparable, patients who exercised submaximally may have 
compromised the sensitivity of the exercise approach. Finally, 
the performance of an exercise test took an average of -7  or 
8 min, whereas that of arbutamine stress took 18 min. In this 
era of attention to productivity and cost-effectiveness, this 
greater than doubling of the stress duration has an impact on 
the number of tests that can be performed in a day and 
therefore on the cost of the test. 
Arbutamine versus dobutamine stress. The main indica- 
tion for arbutamine stress is for stress testing in patients who 
are unable to exercise maximally. As such, it competes with 
dobutamine stress for echocardiography and dobutamine and 
the vasodilator stressors for perfusion scintigraphy. The sensi- 
tivity and specificity of arbutamine stress are comparable to the 
spectrum of accuracy recorded for these alternative stressors. 
Moreover, the side-effect profile of arbutamine stress appears 
to parallel that of dobutamine, with the main serious side 
effects pertaining to heart rhythm disturbances, which were 
fortunately reversible. Although some hopes were initially 
raised that arbutamine might avoid some of the hypotensive 
effects of dobutamine, these side effects have nonetheless 
continued to be troublesome. In relation to the inotropic 
response of arbutamine, a lesser degree of inotropy might have 
the benefit of avoiding the marked reduction i  left ventricular 
volumes associated with peak dobutamine stress, which may 
compromise the ability to identify minor wall motion abnor- 
malities. Whether this is an important clinical benefit of 
arbutamine needs to be determined. Arbutamine has a longer 
half-life than dobutamine and in all probability has a longer 
duration of offset than dobutamine, although this matter has 
not been subjected to a comparative study. Finally, the possi- 
bility of arbutamine inducing ischemia t lower heart rates may 
avoid the need for atropine, but this has not been studied. 
At present, therefore, the major difference between arbu- 
tamine and the alternative agents is in the administration 
protocol. With arbutamine, administration is performed 
through an automated feedback loop that individualizes the 
dosing of arbutamine and thereby takes into account individual 
variability in the drug response. The device automatically 
monitors and records the response to stress and identifies 
situations of potential concern. These properties may decrease 
the number of personnel required for performance ofthe test, 
although this requires independent validation i  future studies. 
Conclusions. The currently used pharmacologic stressors 
have important limitations, and there is a need for another 
stress technique for use in patients who are unable to exercise. 
On the basis of the studies published in this issue of the Journal 
(9-11), arbutamine appears to be an effective "exercise- 
simulating" agent for stress testing in patients who are unable 
to exercise, and it is currently licensed for this use in Europe. 
Subsequent studies will need to address the accuracy of 
arbutamine for stress testing in women, who were poorly 
represented in these studies, as well as comparison with other 
pharmacologic stressors (especially dobutamine) and docu- 
mentation of its efficacy for prognostic stratification. The 
search for an ideal stress agent for patients who are unable to 
exercise should continue. Although arbutamine in combination 
with the closed-loop device shows promise, whether it will 
fulfill the requirements of the "optimal" stress agent remains 
to be established. 
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